 |
|
Personalized approaches to the treatment of hepatocellular carcinoma using immune checkpoint inhibitors: Editorial on “Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial”
Naoshi Nishida
Clin Mol Hepatol. 2025;31(1):311-315. Published online 2024 Sep 3 DOI: https://doi.org/10.3350/cmh.2024.0739
|
|
Citations to this article as recorded by
 Addressing the Complexities of Pre-Liver Transplant Immune Checkpoint Inhibitors for Hepatocellular Carcinoma: A Response to Recent Commentaries
Mohammad Saeid Rezaee-Zavareh, Zhiyong Guo, Ju Dong Yang
Journal of Hepatology.2024;[Epub] CrossRef
|